The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases

N Chalasani, Z Younossi, JE Lavine, M Charlton… - Hepatology, 2018 - journals.lww.com
This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …

Challenges and opportunities in NASH drug development

SA Harrison, AM Allen, J Dubourg, M Noureddin… - Nature medicine, 2023 - nature.com
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

M Eslam, SK Sarin, VWS Wong, JG Fan… - Hepatology …, 2020 - Springer
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders

J Aron-Wisnewsky, C Vigliotti, J Witjes, P Le… - Nature Reviews …, 2020 - nature.com
Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes
mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease …

Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver …

PJ Eddowes, M Sasso, M Allison, E Tsochatzis… - Gastroenterology, 2019 - Elsevier
Background & Aims We estimated the accuracy of FibroScan vibration-controlled transient
elastography controlled attenuation parameter (CAP) and liver stiffness measurement …

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

H Hagström, P Nasr, M Ekstedt, U Hammar, P Stål… - Journal of …, 2017 - Elsevier
Background & Aims Non-alcoholic fatty liver disease (NAFLD) is very common in the general
population, but identifying patients with increased risk of mortality and liver-specific morbidity …

[HTML][HTML] Non-alcoholic fatty liver disease: A patient guideline

SM Francque, G Marchesini, A Kautz, M Walmsley… - JHEP reports, 2021 - Elsevier
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

O Govaere, S Cockell, D Tiniakos, R Queen… - Science translational …, 2020 - science.org
The mechanisms that drive nonalcoholic fatty liver disease (NAFLD) remain incompletely
understood. This large multicenter study characterized the transcriptional changes that occur …

Cellular senescence drives age-dependent hepatic steatosis

M Ogrodnik, S Miwa, T Tchkonia, D Tiniakos… - Nature …, 2017 - nature.com
The incidence of non-alcoholic fatty liver disease (NAFLD) increases with age. Cellular
senescence refers to a state of irreversible cell-cycle arrest combined with the secretion of …

[HTML][HTML] Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis

S Leoni, F Tovoli, L Napoli, I Serio, S Ferri… - World journal of …, 2018 - ncbi.nlm.nih.gov
The current epidemic of non-alcoholic fatty liver disease (NAFLD) is resha** the field of
hepatology all around the world. The widespread diffusion of metabolic risk factors such as …